Last week, Rep. Earl Blumenauer discussed the therapeutic potential of psychedelic drugs as alternatives to traditional drugs for mental health disorders during a House Ways and Means Committee meeting. During the meeting, legislators talked about proposals on family and worker access to health support.
The congressman stated that while he was encouraged by how legislators were moving forward with integrating various reform areas, including outpatient care, there was still a need to advance the search for therapies that could help to better manage mental health conditions; he proposed that psychedelics be included in the healthcare improvements discussion. His statement was made in response to the committee’s discussion.
This isn’t the first time the congressman has highlighted the benefits of psychedelics. Earlier in January, Blumenauer cowrote a bipartisan letter asking that the Drug Enforcement Administration permit patients with terminal illnesses to have access to psilocybin under federal Right-to-Try laws.
This move was supported by a bicameral and bipartisan congressional effort, which reaffirmed the Right-to-Try statute affording these patients access to drugs classified under Schedule I, including psychedelic substances such as psilocybin and cannabis. Other initiatives focusing on psychedelic substances include a recent spending bill and approved amendments to a defense legislation calling for federal agencies to further support research into the therapeutic potential of psychedelic drugs.
Some of the most recent advanced psychedelic reform introducers include the following: Rep. Earl Blumenauer, Rep. Alexandria Ocasio-Cortez, Sen. Brian Schatz and Sen. Cory Booker, all Democrats; and Rep. Nancy Mace, Rep. Matt Gaetz, Sen. Dan Crenshaw and Sen. Rand Paul, all Republicans.
Despite the growing national trend toward psychedelics reform, some legislators feel that Congress still has a long way to go, regardless of what science and public opinion says. It doesn’t help that federal interest isn’t keeping up with the discussion at the state level either.
Rep. Jared Huffman, a supporter of psychedelics reform, stated recently that he believed that natural fungi and plants such as psilocybin held great benefits when utilized in the appropriate setting; he also noted that it was backward and embarrassing how slow some federal legislators were in approaching the issue because they held outdated views on the subject. Huffman explained that evidence from recently conducted studies had shown that psychedelics could be a game changer.
Thus far, studies have found that psilocybin may be useful in managing treatment-resistant depression while MDMA may be effective in the treatment of post-traumatic stress disorder. Companies such as Silo Pharma Inc. (OTC: SILOD) are also conducting their own R&D programs on different psychedelics, so it wouldn’t be surprising if more therapeutic uses of various compounds such as psilocybin are documented.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTC: SILOD) are available in the company’s newsroom at https://ibn.fm/SILO
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.